Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.


Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Manipulating the body’s immune system can lead to elimination of tumors and prevention of tumor recurrence (for a long-lasting cure).

Apexigen’s Immuno-oncology Strategy

Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform  enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we progress toward the ultimate cure for cancer.


October 6, 2021
Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer

October 1, 2021
Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting

September 9, 2021
Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical Officer

Read more news.